NCT05170009View on ClinicalTrials.gov

Baloxavir in Combination With Oseltamivir in Allogenic Bone Marrow Transplant Recipients With Influenza

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

April 22, 2022

Primary Completion Date

January 17, 2024

Study Completion Date

February 7, 2024

Conditions
Influenza
Interventions
DRUG

Baloxavir Marboxil

Weight-adjusted Baloxavir Marboxil (40 mg for patients weighing \<80 kg and 80 mg for those weighing ≥80 kg) at baseline, day 4, and day 7.

DRUG

Placebo

Placebo at baseline, day 4, and day 7.

DRUG

Oseltamivir

Oseltamivir 75 mg twice daily for 10 days.

Trial Locations (1)

10065

Weill Cornell Medicine, New York

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Weill Medical College of Cornell University

OTHER